ClinicalTrials.gg
Status unknownNCT05145179Updated Dec 6, 2021

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

A Phase 1 interventional study of SSGJ-705 in Receptor, ErbB-2, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-06.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
162
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study will consist of two parts: a dose-escalation part (Part 1) and a dose expansion part (Part 2). In both study parts, SSGJ-705 will be administered,the administration duration may be adjusted based on outcomes of previous patients if necessary) followed by safety, PK, PD, potential anti tumor effects and immunogenicity evaluation.

02

Conditions studied

  • Receptor, ErbB-2
03

In context

Lead sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is the lead sponsor of 59 studies on the registry; 22 are open to participants now.

First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 year, male or female.
  • ≥12 weeks (according to Investigator's judgement).
  • Patients with or cytologically confirmed locally advanced or non resectable -expressing Solid Tumors
  • Patients who have at least one (radiation-naïve) according to v1.1
  • performance status 0-1
  • Adequate organ and bone marrow function evaluated by laboratory tests
  • Male patients who are surgically sterilized or who agree to use highly effective measures during the study and for at least 6 months after administration of the last study drug dose
  • Willing to provide written and willing and able to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

  • Receive chemotherapy, targeted therapy, or other antitumor therapy within 3 weeks prior to initial dosing
  • Patients whose toxicity due to previous anticancer therapy has not been reduced to Grade 1 or lower, or any greater than NCI CTCAE 1 AE exists within 2 weeks before enrollment, not including hair loss and fatigue
  • Patients requiring systemic systemic therapy with systemic hormones or other agents within 4 weeks prior to initial administration and during the study period
  • Previous cumulative doses of adriamycin > 720 mg/m2, adriamycin >360 mg/m2 or other cumulative doses of adriamycin were converted to equal doses of adriamycin >360 mg/m2
  • Patients who underwent major surgery within 4 weeks of initial dosing and have not fully recovered or who plan to undergo major surgery during the trial
  • In addition to palliative radiotherapy, other anticancer treatments not specified in the protocol are planned for the duration of the trial
  • Always received total pelvic radiotherapy
  • Had an active or prior or inflammatory disease within the last 3 years prior to study treatment
  • Severe disease of cardiovascular and cerebrovascular diseases
  • History of active tuberculosis
  • A history of (non-infectious) pneumonia/interstitial pneumonia or a history of present pneumonia/interstitial pneumonia requiring treatment
  • Severe dyspnea or the need for supplemental oxygen therapy at rest due to complications of advanced ; Newly diagnosed or symptomatic central nervous system (CNS) , spinal cord compression, or cancerous meningitis
  • Persons with a history of primary immunodeficiency disease, including but not limited to -positive serum
  • virus (HBV) and virus (HCV) positive subjects
  • Women/men who are pregnant or breast-feeding or planning to give birth
  • A history of mental or substance abuse that may affect study compliance
  • Allergy to other antibody drugs or to any in the study drug
  • Who received within 30 days prior to initial administration (within 72 hours for COVID-19 vaccine), or who plan to receive any live vaccine during the study
  • Previous organ and stem cell transplants (except transplants that do not require immunosuppressive therapy, such as corneal and hair transplants)
  • Participated in any medical device or drug clinical study within 1 month prior to screening
  • The inestigators considered that this would significantly increase the risk of administration of the drug, or that it would affect efficacy evaluation or other conditions requiring exclusion
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    HER2-expressing Solid Tumors

    SSGJ-705 Administered via intravenous (IV) infusion

    Drug: SSGJ-705

Interventions

06

What researchers measure

Primary outcomes

  1. DLT

    Dose-limiting toxicity(part 1)

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. MTD

    maximum tolerated dose(part 1)

    Time frame: up to 1 years

  3. RP2D

    Objective response rate (ORR) per RECIST 1.1 criteria according to investigators recommended Phase II dose(part 1)

    Time frame: up to 1 years

  4. ORR

    Objective response rate (ORR) per RECIST 1.1 criteria according to investigators assessment(part 2)

    Time frame: up to 1 years

Secondary outcomes

  1. Adverse events

    the safety of SSGJ-705 in patients with advanced or metastatic HER2-expressing solid tumors who have failed standard treatment

    Time frame: up to 1 years

  2. Maximum Plasma Concentration (Cmax)

    To evaluate the Cmax of single and multiple doses of SSGJ-705 in patients with advanced or metastatic HER2 expressing solid tumors who have failed standard treatments

    Time frame: up to 1 years

  3. Area Under the Curve (AUC)

    To evaluate the AUC of single and multiple doses of SSGJ-705 in patients with advanced or metastatic HER2 expressing solid tumors who have failed standard treatments

    Time frame: up to 1 years

  4. incidence of anti-609A antibodies

    incidence of anti-609A antibodies

    Time frame: up to 1 years

  5. Median Progression-free Survival (PFS)

    The Kaplan-Meier method will be used to estimate median PFS.

    Time frame: up to 1 years

  6. Overall Survival (OS)

    The Kaplan-Meier method will be used to estimate median OS.

    Time frame: up to 1 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2021; primary completion for Dec 2023, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2021
First posted
Dec 6, 2021
StartEst.
Dec 1, 2021
Primary completionEst.
Dec 1, 2023
CompletionEst.
Jun 1, 2024
Last update
Dec 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05145179
Responsible party
Sponsor
First posted
Dec 6, 2021
Start date
Dec 1, 2021 (estimated)
Primary completion
Dec 1, 2023 (estimated)
Completion
Jun 1, 2024 (estimated)
Last update
Dec 6, 2021

Study contacts

Lili Zheng, PMD
Contact
zhenglili@3sbio.com
18511272561
Zefei Jiang, PhD
principal investigator · The Fifth Medical Center of the People's Liberation Army
Ying Cheng, PhD
principal investigator · Jilin Provincial Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705

Start the discussion